Hepatocellular carcinoma

Research output: Contribution to journalReview article

500 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

Original languageEnglish (US)
Pages (from-to)1253-1257
Number of pages5
JournalLancet
Volume353
Issue number9160
DOIs
StatePublished - Apr 10 1999

Fingerprint

Hepatitis C
Hepatocellular Carcinoma
Viruses
Virus Diseases
Hepatitis B
Hepatitis B virus
Liver Diseases
Vaccination
Vaccines
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatocellular carcinoma. / Schafer, Daniel Francis; Sorrell, Michael Floyd.

In: Lancet, Vol. 353, No. 9160, 10.04.1999, p. 1253-1257.

Research output: Contribution to journalReview article

Schafer, Daniel Francis ; Sorrell, Michael Floyd. / Hepatocellular carcinoma. In: Lancet. 1999 ; Vol. 353, No. 9160. pp. 1253-1257.
@article{c7802269787f4397b2954976b2aaf485,
title = "Hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.",
author = "Schafer, {Daniel Francis} and Sorrell, {Michael Floyd}",
year = "1999",
month = "4",
day = "10",
doi = "10.1016/S0140-6736(98)09148-X",
language = "English (US)",
volume = "353",
pages = "1253--1257",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9160",

}

TY - JOUR

T1 - Hepatocellular carcinoma

AU - Schafer, Daniel Francis

AU - Sorrell, Michael Floyd

PY - 1999/4/10

Y1 - 1999/4/10

N2 - Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

AB - Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

UR - http://www.scopus.com/inward/record.url?scp=0033541491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033541491&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(98)09148-X

DO - 10.1016/S0140-6736(98)09148-X

M3 - Review article

C2 - 10217098

AN - SCOPUS:0033541491

VL - 353

SP - 1253

EP - 1257

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9160

ER -